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Pulmonary sclerosing hemangioma (PSH) is a rare benign tumor of the lungs. These tumors are composed of
cuboidal surface cells and polygonal stromal cells and show four histological manifestations: hemorrhagic, papillary,
solid, and sclerotic. PSH predominantly affects asymptomatic middle-aged women. The tumor often occurs at the
intralobar site, and less commonly in the bronchus and mediastinum. PSH is easy to be misdiagnosed
preoperatively. In this study, we present in detail the treatment procedures followed for two atypical cases of PSH.
Case 1 was a 62-year-old woman bearing a tumor for 15 years. The tumor lesion was found to be located in the
oblique fissure of the left lung. PSH was confirmed by surgical resection and postoperative pathological diagnosis.
There was no sign of recurrence and metastasis 1.5 years after surgery. Case 2 was a 54-year-old woman diagnosed
with bilateral multiple nodules by physical examination. This patient was diagnosed with definite PSH through
computed tomography-guided percutaneous lung biopsy. Surgical resection was not performed. The patient also
showed no sign of enlarged tumor and metastasis after 2 years of follow-up. Although PSH can be cured by
surgical resection, the findings in our cases indicate that surgical resection need not be considered the preferred
course of treatment. If PSH is diagnosed before surgery, the patients may survive while bearing the tumor.
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PathologyBackground
Pulmonary sclerosing hemangioma (PSH) is an uncom-
mon benign tumor, which was first described by Liebow
and Hubbell in 1956 [1]. Various scholars have suggested
that this tumor originates from vascular endothelial,
mesothelial, mesenchymal, epithelial, or neuroendocrine
cells. Recently, other reports have provided evidence sup-
porting the theory that PSH originates from type II pneu-
mocytes. Although PSH is categorized as a miscellaneous
tumor according to the 2004 World Health Organization
classification of lung tumors, its etiology and origin re-
main controversial. PSH can be easily misdiagnosed pre-
operatively. PSH can be misdiagnosed as a malignant
tumor during intraoperative frozen-section assessment
and has a misdiagnosis rate of 25 to 56%, which results in
unnecessary extensive surgical procedures and malignant
biological behaviors, including local lymph-node* Correspondence: huangxuequan02@gmail.com
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reproduction in any medium, provided the ormetastasis and tumor recurrence [2-7]. Definite diagnosis
of cases of bilateral multiple PSH is usually possible after
postoperative histopathological examination. Cases are
seldom diagnosed by performing computed tomography
(CT)-guided percutaneous lung biopsy because of the in-
sufficient tissue at the puncture site. There are few reports
about the PSH developing in the oblique fissure in lungs,
with patients bearing such tumors for more than 15 years.
Here we report two cases of PSH and explore the clinical
management of PSH.Case presentation
Case 1
The patient was an asymptomatic 62-year-old woman
diagnosed with a tumor in the left hilum of the lung in
1995, who had refused to undergo treatment (imaging
data of the physical examination had been misplaced). A
chest radiograph obtained in 1999 indicated multiple ab-
normal nodular shadows in the left hilar field; the shadows
were approximately 2.5 cm×3 cm in size, which, in com-
bination with the patient’s description of the originalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Computed tomography scan of Case 1 obtained in
2010. Computed tomography scan obtained in 2010 showing a
huge soft-tissue mass with a clear periphery in the left side of the
chest, measuring 8.2 cm× 8.6 cm.
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sized. A chest radiograph obtained in 2001 showed a slight
increase in the lesion size. The tumor measured about
7 cm×8 cm in 2009 (Figure 1). A CT scan obtained in
2010 showed a giant soft-tissue mass in the left side of her
chest, measuring 8.2 cm×8.6 cm with scattered calcifica-
tions at the edge (Figure 2). No positive results were
obtained from any of the laboratory examinations con-
ducted when the patient was admitted to the hospital. On
intraoperative examination, a well-circumscribed hard
tumor measuring 10 cm×10 cm×10 cm was found to be
located in the fissure of the left lung; the tumor was found
to be adhered to the superior lobe, inferior lobe, and pos-
terior chest wall. A vascular endothelial tumor was diag-
nosed on the basis of intraoperative frozen-section
analysis. PSH was confirmed by surgical resection and
postoperative pathological diagnosis of a paraffin-
embedded section, in which hemorrhagic, papillary areas
appeared (Figure 3A). The immunohistochemical results
were as follows: thyroid nuclear factor 1 (positive;
Figure 3B), cytokeratins (negative), vimentin (positive),
CD34 (positive), synaptophysin (negative), and epithelial
membrane antigen (positive). The patient was discharged
from the hospital after 8 days, without receiving any fur-
ther adjuvant therapy after the surgery. One and a half
years after the surgery, a CT scan indicated good expan-
sion of the left lung and no sign of recurrence and metas-
tasis (Figure 4).
Case 2
A 54-year-old woman underwent chest CT as a part of
physical examination. Round-shaped nodular shadows
were observed in the medial and lateral segments of the
middle lobe of the right lung and the basal segment of
the left lower lobe, with diameters of 2.5 cm, 0.9 cm,
and 0.8 cm, respectively. No tumors were observed in
the periphery, and point-like calcification was observed
in the two nodules in the middle lobe of the right lung
(Figure 5). Negative results were obtained in the analysisFigure 1 Chest radiograph of Case 1 obtained from 1999 to 2009. Ch
enlargement in the size of the nodule from its size in 1999.for all tumor markers. CT-guided percutaneous lung bi-
opsy was performed on the lesion in the middle lobe of
the right lung. The biopsy results indicated the develop-
ment of PSH. Three of the histological characteristics
appeared in a paraffin-embedded section (Figure 6). The
results of immunohistochemical analyses were as fol-
lows: thyroid nuclear factor 1 (positive), synaptophysin
(negative), CD56 (negative), CD68 (positive), cytokera-
tins (positive), and P63 (negative). This patient was
therefore diagnosed with bilateral multiple PSH and was
discharged from the hospital without any further adju-
vant therapy. Two-year follow-up found no increase in
the number and size of the lesions.Discussion
PSH is a rare benign neoplasm of the lung. The origin of
PSH has remained controversial despite extensive studies
by many investigators. PSH can occur in any individual
in the age group of 4 to 70 years [8, 9]. PSH is predomin-
ant in 50 year olds, with a female to male ratio of 5:1 in
this patient group [10]. Most of the PSH patients areest radiograph of the first patient obtained in 2009 showing a gradual
Figure 3 Pulmonary sclerosing hemangioma was confirmed by surgical resection and postoperative pathological diagnosis. (A) Two of
the typical histological characteristics: hemorrhagic and papillary areas (×100). (B) Both the cuboidal surface cells and polygonal cells showed
thyroid nuclear factor 1 staining (×200).
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tions, including cough, hemoptysis, chest pain, and stuffi-
ness. The observations of the two cases from this study
were in accordance with those from previous studies. Both
the patients were women with an average age of 50.5 years
when they visited a doctor initially, and they were diag-
nosed with PSH after a physical examination.
PSH is mainly composed of two types of cells: cuboidal
surface cells that tend to differentiate into type II pneu-
mocytes, and polygonal stromal cells that have consider-
able multilineage differentiation potential [11]. In the
histopathological analysis, both surface-lining cuboidal
cells and pale polygonal cells stained positive for thyroid
nuclear factor 1, whereas only some of the cells stained
positive for vimentin, epithelial membrane antigen,
CD68, and cytokeratins. Wang and colleagues suggested
that these differences in morphology and phenotype mayFigure 4 Computed tomography scan of Case 1 obtained in
2011. Computed tomography scan obtained in 2011 indicating
good expansion of the left lung and a fibrous lesion in the area on
which surgery was performed.be attributed to the differences in the status of the cu-
boidal and polygonal cells [11]. PSH is histologically
characterized by the presence of hemorrhagic, papillary,
solid, or sclerotic areas. Most tumors show at least three
of these histological characteristics, as also shown in our
two cases.
Imaging data for the first case indicated a gradual in-
crease in the lesion size, but the patient did not experience
any special discomfort. To date there has been no report
of a patient bearing a tumor for 15 years in the oblique
fissure area of the lungs. In our first patient, there was no
sign of lung and lymph-node metastasis, suggesting that
PSH may be showing benign biological characteristics,
such as poor growth, non-invasiveness, and nonmetasta-
sis. However, there was evidence indicating that PSH is ac-
companied by lung or lymph-node metastasis and the
etiology of PSH is still unclear, while metastasis of this
tumor has no effect on patient survival [4, 5]. Intraopera-
tive analysis indicated a well-circumscribed hard tumor in
the oblique fissure of the left lung; the tumor was found
to be adhered to the superior lobe, inferior lobe, and the
posterior chest wall. Since PSH is known to be composed
of cuboidal surface cells and polygonal stromal cells and is
derived from type II pneumocytes, we predicted this
tumor might have originated in the subpleural lung region
of the visceral pleura and then spread to the oblique
fissure due to prolonged compression and adhesion to the
adjacent structure by the tumor. This case should be dif-
ferentiated from Castleman disease and pulmonary
hamartoma. Castleman disease commonly manifests as an
elliptical soft-tissue mass showing a radial or stellate calci-
fication in the central region of the lesion. The presence
of fat density within a nodule and the presence of
popcorn-like calcifications are specifically indicative of
pulmonary hamartoma.
In the second patient, the CT scan showed round-
shaped nodular shadows in the middle lobe of the right
lung and in the lateral and basal segments of the left
Figure 5 Computed tomography scan of Case 2. Multiple pulmonary sclerosing hemangioma in the medial and lateral segments of the
middle lobe of the right lung and in the basal segment of the left lower lobe.
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respectively. In addition, the periphery was clear and
point-like calcification was observed in the two nodules in
the middle lobe of the right lung. CT-guided percutaneous
lung biopsy was performed only on the nodule in the
medial segment of the middle lobe of the right lung. On
the basis of the clinical features and the pathological
results, this patient was diagnosed with bilateral multiple
PSH, which can coexist with lung cancer or can even
occur in the same cancerous lesion [12,13]. A similar case
has been reported previously [14], but pulmonary lobec-
tomy was performed in that study to diagnose the path-
ology. The residual nodules showed no changes after
10 years of follow-up. Another study showed tumor recur-
rence 10 years after resection [3]. Since this condition has
multiple probable outcomes, further follow-up should beFigure 6 Pulmonary sclerosing hemangioma was confirmed by
CT-guided percutaneous lung biopsy postoperative pathological
diagnosis. Papillary areas: cuboidal cells were on the papillary
surface and polygonal cells were in the stroma (×200).performed in our patient to thoroughly understand the
biological behavior of PSH, which may help determine
whether surgical resection or other methods need to be
performed. This case should be differentiated from tuber-
culoma and metastatic tumors. Usually, tuberculoma
patients have a history of tuberculosis at a specific loca-
tion. A metastatic tumor also usually has a history of a pri-
mary tumor.
Conclusions
Surgical resection is currently widely used for treating
PSH, and no study has reported distant metastasis and
the effect of surgical resection on patient survival. How-
ever, PSH predominantly affects middle-aged individuals
whose lung function may be bad, and the misdiagnosis
rate by intraoperative frozen-section assessment is high,
resulting in unnecessary extensive surgical procedures
and discomfort for the patients. We therefore suggest
that surgical resection should not be considered the pre-
ferred strategy for treating single or multiple PSH in the
intralobar sites or oblique fissure. If PSH is diagnosed
before surgery, and the lesion has no effect on the
patient’s respiratory function, the patients can survive
bearing the tumor.
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